Logo
x

Search

Subscribe Now

Approval

Insights+ Key Biosimilars Events of December 2023

Insights+ Key Biosimilars Events of December 2023

  • January 9, 2024
Insights+ Key Biosimilars Events of November 2023

Insights+ Key Biosimilars Events of November 2023

  • December 7, 2023
Insights+: The US FDA New Drug Approvals in October 2022

Insights+: The US FDA New Drug Approvals in October 2022

  • November 17, 2022
Samsung Bioepis’s Ontruzant (biosimilar, trastuzumab) Receives the Health Canada Approval for the Treatment of Breast & Gastric Cancer

Samsung Bioepis’s Ontruzant (biosimilar, trastuzumab) Receives the Health Canada Approval for the Treatment of Breast & Gastric Ca...

  • February 2, 2022
Merck's Keytruda (pembrolizumab) Receives the US FDA's Approval as an Adjuvant Therapy for Renal Cell Carcinoma

Merck's Keytruda (pembrolizumab) Receives the US FDA's Approval as an Adjuvant Therapy for Renal Cell Carcinoma

  • November 19, 2021
Antengene's Selinexor (ATG-010) Receives NMPA's IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Antengene's Selinexor (ATG-010) Receives NMPA's IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

  • November 19, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.